General Atlantic’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

General Atlantic’s Portfolio KRSA Stock Details KRSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$43.7M	Buy	+1,366,242	New	+$37.9M	1.76%	11

Other funds holding KRSA

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return

Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return

Remedium Capital Partners Fort Lauderdale, Florida $274M AUM 288.41% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $132M AUM 92.09% 1-Year Est. Return

Spruce Street Capital New York $629M AUM 210.46% 1-Year Est. Return

Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return

NEXTBio Capital Management Menlo Park, California $234M AUM 176.49% 1-Year Est. Return

Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return

General Atlantic's KRSA Position: Q3 2026 in Review

General Atlantic opened a new position in Korsana Biosciences, Inc. Common Stock (KRSA) in Q3 2026: 1,366,242 shares worth $43.7M. The stake represents 1.76% of the portfolio and ranks #11 among its holdings.

24 funds tracked by Wall St. Rank hold KRSA as of Q3 2026.

General Atlantic held 1,366,242 shares of Korsana Biosciences, Inc. Common Stock worth $43.7M as of Q3 2026.
Korsana Biosciences, Inc. Common Stock was a new General Atlantic position in Q3 2026.
Korsana Biosciences, Inc. Common Stock made up 1.76% of General Atlantic's portfolio in Q3 2026, its #11 holding.
24 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q3 2026.

Based on General Atlantic's 13F filing for Q3 2026, filed 13 Nov 2026.